Eli Lilly Expands AI Drug Discovery Deal with Insilico for up to $2.75bn
Eli Lilly will pay Insilico Medicine a $115m upfront fee and up to $2.75bn in milestones and tiered royalties under an expanded AI drug discovery agreement. The deal grants Lilly an exclusive worldwide license to develop, manufacture and commercialize preclinical oral treatments identified by Insilico’s AI engine.
1. Expanded Insilico Collaboration
Under the agreement, Lilly will pay $115m upfront to Insilico Medicine, with development, regulatory and commercial milestones that could total $2.75bn, plus tiered royalties on future sales. The deal grants Lilly an exclusive worldwide license to develop, manufacture and commercialize certain preclinical oral treatments identified by Insilico’s AI platform.
2. Strategic Pipeline Acceleration
By integrating Insilico’s AI engine, Lilly aims to identify multi-purpose targets across multiple diseases and fast-track oral drug candidates into clinical trials, bolstering its early-stage pipeline and leveraging AI to reduce discovery timelines and costs.